• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vast Therapeutics closes Series A for nitric oxide powder tech

December 6, 2018 By Sarah Faulkner

Vast Therapeutics logoVast Therapeutics said today that it finished a Series A round with investment from Japan-based Shionogi & Co.

The company plans to use the round’s proceeds to bring their nitric oxide powder technology through preclinical testing and first-in-human clinical safety and efficacy trials.

Vast Therapeutics’ technology, which was in-licensed from the University of North Carolina at Chapel Hill, is designed to combat bacteria that cause respiratory infections. The company’s first focus is to develop a nitric oxide-based drug for cystic fibrosis patients who experience chronic pseudomonas aeruginosa infections.

“Our objective is to completely disrupt the paradigm of treating infections. Our technology can solve a major problem at a time when that problem is creating a dire situation for public health,” Vast’s CEO & chairman, Neal Hunter, said in prepared remarks. “We’ve always realized that it would take more than one company to optimize our technology and Shionogi’s commitment to anti-infectives puts them in a small class of larger pharmaceutical companies who have an ability to develop advanced pharmaceutical products and bring them to market quickly.”

“We’ve had a keen interest in nitric oxide technology for some time. In Vast we have found a technology, intellectual property portfolio, and management team that could help us change the anti-infective market,” Dr. Takeshi Shiota, SVP of Shionogi’s pharmaceutical research division, added.

“From our first meeting with Shionogi earlier this summer, we were impressed with their scientific acumen and research-driven approach to drug development. Regarded as one of the top developers of anti-infective products, Shionogi showed us that they were nimble and capable of working with incredible pace and focus making them the right partner to fully develop nitric oxide pulmonary anti-infectives,” said Vast’s director of business development & IP, Kyle Kimble.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: vasttherapeutics

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS